NCT07397377Recruiting
prTMS as an Intervention for Bradykinesia in Parkinson's Disease
Enhancing rTMS Effects Through a State-Dependent Approach - An Intervention for Bradykinesia in Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
This study investigates the use of patterned repetitive transcranial magnetic stimulation (prTMS) as an intervention for bradykinesia in Parkinson's Disease (PD). More specifically, the study aims to determine whether prTMS over the supplementary motor area (SMA) can reduce severity of bradykinesia in PD patients. This approach may open for more targeted and effective treatment of bradykinesia in PD.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- First submitted
- 21 Jan 2026
- Start date
- 16 Dec 2025
- Primary completion date
- 1 May 2027
- Lead sponsor
- Danish Research Centre for Magnetic Resonance
- Diseases
- Parkinson disease
- NCT number
- NCT07397377
What you commit to
- Study type: Interventional
- Planned participants: 27
- From 16 Dec 2025 to the primary completion date, 1 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Psychiatric disorders. Current use of antipsychotic medication, Donepezil, or GABAergic agents (e.g., pregabalin, gabapentin).
- History of neurological disease other than PD. Past or present mental illness. History of epilepsy/conditions associated with increased risk of seizure induction through transcranial magnetic stimulation (TMS).
- Close relatives suffering from epilepsy/conditions associated with increased risk of seizures.
Age
- Contraindications for magnetic resonance imaging (MRI) Contraindications for TMS Female participants of childbearing age must not be pregnant and must use contraception during the trial.
Other
- Frequent benzodiazepine or opioid use defined as more than once per week on a regular basis.
- Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation in the study.
Who the study is looking for
- Above 18 years of age. Clinically established or probable Parkinson's Disease (PD), according to the Movement Disorder Society.
- Clinical Diagnostic Criteria for PD. Stable antiparkinsonian medicine for at least four weeks. Signed informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| DRCMR Coordinator of this site? Confirm its status | Hvidovre | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.